Newsroom | Galderma US

RESTYLANE® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers

Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

Cetaphil® Announces Major Evolution in Brand’s Mission to Advance Sensitive Skin Science

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Galderma receives FDA approval for Restylane® Contour for cheek augmentation and correction of midface contour deficiencies

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Cetaphil® Champions Sun Protection Awareness and Education with Dermatologist-led Digital Campaign

Cetaphil® Launches Innovative Digital Campaign to Connect with Millions of Consumers Experiencing Skin Sensitivity

Differin® Celebrates Fourth Annual Retinoid Education Week by Offering People with Acne the Chance to “Get Clear” Through Large-Scale Product Giveaway

Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation

Galderma Announces Launch of Face for Change Program

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)